CVS Health Corporation is a health solutions company operating through four reportable segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. The Health Care Benefits segment, operated through Aetna, provides traditional, voluntary, and consumer-directed health insurance products, including medical, pharmacy, dental, and behavioral health plans, as well as Medicare Advantage, Medicare Supplement, and standalone Medicare Part D prescription drug plans. The Pharmacy & Consumer Wellness segment operates retail pharmacy locations and offers prescription delivery and specialty medication services. The Health Services segment includes walk-in and primary care medical clinics. The company serves employer groups, government-sponsored plans, and individual consumers across the United States, with Medicare Advantage plans offered in 44 states and Washington, D.C., and Medicare Part D plans available in all 50 states and Washington, D.C. Key brands include Aetna, CVS Pharmacy, and CVS Caremark, the latter serving as a pharmacy benefits manager.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Healthcare Plans Homepage cvshealth.com
Sector Healthcare IR page investors.cvshealth.com/overview/default.aspx
Tags
health insurance, pharmacy benefits management, retail pharmacy, primary care clinics, medicare advantage, medicare part d, medicaid, specialty pharmacy, behavioral health, dental insurance, Aetna, CVS Pharmacy, CVS Caremark
Press page cvshealth.com/news

Metrics

Valuation  
Market cap $ 107.386B
Market cap (USD) $ 107.386B
P/E 9.76
PEG —
P/BV 1.33
P/S 0.26
P/OCF 5.74
P/FCF 6.90
Dividend yield 3.2%
Turnover / mcap —
Returns  
ROE 2.3%
ROI 1.3%
ROIC 2.7%
Profit margin 0.44%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -24.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 85.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 49
Quality score 31.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 402.067B 372.809B 357.776B 322.467B 292.111B 268.706B 256.776B 193.919B 184.765B 177.526B 153.29B 139.367B 126.761B 123.133B 107.1B 96.413B 98.729B 87.472B 76.33B 43.814B 37.006B 30.594B 26.588B 24.182B 22.241B 20.088B 18.098B
Net profit 1.768B 4.614B 8.344B 4.149B 7.91B 7.179B 6.634B -594M 6.622B 5.317B 5.239B 4.644B 4.592B 3.875B 3.457B 3.427B 3.696B 3.212B 2.637B 1.369B 1.225B 918.8M 847.3M 716.6M 413.2M 746M 635.1M
Free cash flow 7.807B 6.326B 10.395B 13.45B 15.745B 13.428B 10.391B 6.828B 6.089B 7.845B 6.045B 6.001B 3.799B 4.641B 3.984B 2.774B 1.487B 1.767B 1.424B -26.5M 116.7M -433.5M -152.8M 96M -33M 84.9M 165.3M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 79.36 44.89 78.96 93.19 103.16 68.3 74.29 65.52 72.5 78.91 97.77 96.31 71.57 48.35 40.78 34.77 32.21 28.73 42.05 29.68 — — — — — — —
Price performance 12m 0.77 -0.43 -0.15 -0.1 0.51 -0.08 0.13 -0.1 -0.08 -0.19 0.02 0.35 0.48 0.19 0.17 0.08 0.12 -0.32 0.42 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 12.2B 13.2B 17.6B 19.6B 21.7B 24.4B 27.3B 35.2B 36.5B 39.8B
↳ YoY growth +2.3% +8.4% +33.8% +11.3% +10.8% +12.4% +11.6% +29.2% +3.5% +9.1%
↳ 5y CAGR +15.0% +15.3% +15.1% +15.2% +12.8% +15.0% +15.7% +14.8% +13.2% +12.8%
Borrowings, current (USD) 1.92B 4.82B 1.99B 3.78B 5.44B 4.21B 1.78B 400M 4.24B 0.00
Borrowings, non-current (USD) 25.6B 22.2B 71.4B 64.7B 59.2B 52B 50.5B 58.6B 60.5B 60.5B
Lease liabilities (USD) — 306M 269M 21.3B 21.5B 21.1B 19.9B 19.2B 18B 16.7B
Cash and deposits (USD) 3.37B 1.7B 4.06B 5.68B 7.85B 9.41B 12.9B 8.2B 8.59B 8.45B
Intangible assets (USD) 13.5B 13.6B 36.5B 33.1B 31.1B 29B 24.8B 29.2B 27.3B 25.5B
Right-of-use assets (USD) — — 0.00 20.9B 20.7B 19.1B 17.9B 17.3B 15.9B 15B
Net debt (borrowings + leases - cash) (USD) 24.2B 25.3B 69.6B 84.1B 78.3B 67.9B 59.3B 70B 74.2B 68.8B
Cash flow detail
Operating cash flow (USD) 10.1B 8.01B 8.87B 12.8B 15.9B 18.3B 16.2B 13.4B 9.11B 10.6B
Purchases of property, plant and equipment (USD) -2.22B -1.92B -2.04B -2.46B -2.44B -2.52B -2.73B -3.03B -2.78B -2.83B
Change in receivables (cash effect) (USD) -243M -941M -1.14B -2.16B -1.51B -2.7B -2.97B -6.26B -1.3B -3.5B
Change in inventories (cash effect) (USD) -742M -514M -1.15B -1.08B -973M 735M -1.44B 1.23B -102M -1.27B
Change in payables (cash effect) (USD) 2.19B 1.71B 2.49B 3.55B 2.77B 2.9B 4.26B 3.62B 2.34B 3.86B
Dividends paid (cash effect) (USD) -1.84B -2.05B -2.04B -2.6B -2.62B -2.63B -2.91B -3.13B -3.37B -3.4B
Share buybacks (cash effect) (USD) -4.46B -4.36B 0.00 0.00 0.00 0.00 -3.5B -2.01B -3.02B 0.00
Interest paid (cash effect) (USD) -1.14B -1.07B -2.8B -2.95B -2.9B -2.47B -2.24B -2.42B -2.91B -2.99B
Income taxes paid (cash effect) (USD) -3.06B -2.91B -2.38B -2.72B -2.93B -3.2B -4.12B -3.52B -1.7B -2.17B
Share-based compensation (USD) 222M 234M 280M 453M 400M 484M 447M 588M 540M 535M
Operating cash flow before change in receivables (USD) 10.3B 8.95B 10B 15B 17.4B 21B 19.1B 19.7B 10.4B 14.1B
Free cash flow (OCF - PPE - intangibles) (USD) 7.85B 6.09B 6.83B 10.4B 13.4B 15.7B 13.5B 10.4B 6.33B 7.81B
Income detail
Total comprehensive income (USD) 5.37B 6.76B -322M 7.55B 7.59B 7.45B 1.74B 9.34B 4.76B 2.25B
Comprehensive income to owners (USD) 5.37B 6.76B -320M 7.55B 7.57B 7.46B 1.72B 9.31B 4.79B 2.29B
Provision for credit losses (USD) 221M 177M 256M 111M — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 1.8% 1.4% 1.7% 0.6% — — — — — —
Reported Feb 28, 2019 Feb 28, 2019 May 1, 2019 Feb 18, 2020 Feb 8, 2023 Feb 8, 2023 Feb 8, 2023 Feb 7, 2024 Feb 12, 2025 Feb 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

CVS Caremark is expanding access and affordability with biosimilars Bull 1 Bear 0 Product/operations

November 6, 2026 |2 minute read

Child and adult unpack a CVS Pharmacy delivery box together at home.

As health care leaders work to expand access and improve affordability, biosimilars are creating new opportunities to help patients access the treatments they need. By increasing competition and expanding treatment options, biosimilars are helping to make high-quality care more accessible across the health care system.

Key findings from the CVS Caremark-Employee Benefit News Biosimilar Study

A recent survey conducted by CVS Caremark and Employee Benefit News (EBN) highlights the growing momentum behind biosimilars. Nearly half of employers surveyed said they currently encourage coverage of biosimilars, while another 40% are actively considering or exploring the approach as part of their pharmacy benefit strategy. The findings reflect a broader recognition that biosimilars can help address one of health care's most pressing challenges: how to expand access to treatment while managing costs.

Biosimilars are FDA-approved medications that are highly similar to an existing biologic medicine and have no clinically meaningful differences in safety, effectiveness or quality. While biologics have transformed care for many complex and chronic conditions, they also represent a significant share of prescription drug spending. Biosimilars may offer a lower-cost alternative that can help make these therapies more accessible for patients and more sustainable for employers and health plans.

The opportunity is especially important in specialty pharmacy, where high-cost therapies continue to drive health care spending. In the CVS Caremark-EBN survey, employers identified expanding access to affordable specialty medications as one of the greatest opportunities for pharmacy benefit managers to improve. Forty-three percent also said specialty drug access is a top consideration when choosing a PBM partner.

How CVS Caremark is Expanding Biosimilar Access and Affordability

CVS Health has taken a leading role in advancing biosimilar adoption. In 2024, CVS Caremark became the first pharmacy benefit manager to remove Humira® from major national commercial template formularies in favor of biosimilars. The strategy helped accelerate adoption of lower-cost alternatives and generated significant savings for clients and members. CVS Caremark reports that its biosimilar approach has helped clients and members realize approximately $3.3 billion in gross savings while maintaining access to treatment.

CVS Caremark has also expanded biosimilar adoption into additional therapeutic areas, including osteoporosis, multiple sclerosis and rare blood disorders, helping increase access to lower-cost treatment options. More recently, CVS Caremark updated key commercial formularies to prefer lower-cost interchangeable biosimilars over Stelara®. The change is designed to improve affordability while maintaining access to clinically appropriate care, with most affected members expected to pay no out-of-pocket costs for their therapy.

What the Study Means for Specialty Drug Costs

These examples demonstrate how competition can help improve affordability across the health care system. For patients, biosimilars can reduce financial barriers to needed medications. For employers and health plans, they offer another tool to help manage specialty drug costs while maintaining access to proven therapies.

As more biosimilars enter the market, they are helping shape a health care system that better balances affordability, access and clinical excellence. By expanding access to proven lower-cost alternatives while maintaining high standards of care, biosimilars represent a meaningful opportunity to improve outcomes for patients and create a more sustainable future for health care.

Related tags

Get our latest news

Sign up for our newsletter

Thank you for subscribing. There seems to be a problem. Please try again later.

Tackling public health challenges with heart

onetrust

Privacy Preference Center

We use certain technologies including necessary cookies on this site that collect data from and about you. These cookies cannot be disabled and we use this information to make our website work. We would also like to set optional cookies to help us understand how you engage with our site, to improve and personalize the services we offer you, record your site interactions, and to display tailored advertising based on your user behavior. We do not turn these optional cookies on unless you accept them.

Manage Consent Preferences

Strictly Necessary

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Marketing & Advertising Cookies

Marketing & Advertising Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

November 4, 2026

  • Third quarter total revenues increased to $108.4 billion, up 5.4% year-over-year
  • Third quarter GAAP diluted EPS of $1.68 and Adjusted EPS of $2.09
  • Generated year-to-date cash flow from operations of $15.3 billion
  • Raising full-year 2026 guidance:
    • GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04
    • Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10
    • Cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion

WOONSOCKET, R.I., Nov. 4, 2026 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2026.

"Our colleagues build trust every day through delivering quality health care rooted in our purpose - to simplify health care one person, one family and one community at a time. Through their continued dedication, each of our businesses delivered another quarter of strong results. We continue to advance our strategy by improving the consumer experience, lowering health care costs, and connecting care for the people we serve."
                                                                                           

- David Joyner, CVS Health Chairman and CEO

Three Months EndedSeptember 30, Year EndingDecember 31,
In billions, except per share amounts 2026 2025 2026 Projected
Total revenues $     108.4 $     102.9 At least $420.0
Diluted earnings (loss) per share $      1.68 $     (3.13) At least $6.98
Adjusted EPS(2) $      2.09 $      1.60 At least $8.20

Third quarter GAAP diluted earnings per share of $1.68 increased from a loss per share of $3.13 in the prior year, reflecting the absence of a $5.7 billion goodwill impairment charge recorded in the third quarter of 2025. Adjusted EPS of $2.09 increased from $1.60 in the prior year, primarily due to improved adjusted operating income in the Health Care Benefits segment, reflecting continued execution of its margin recovery plan.

The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.

Consolidated third quarter results

Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
In millions, except per share amounts 2026 2025 Change 2026 2025 Change
Total revenues $ 108,399 $ 102,871 $   5,528 $ 314,921 $ 296,374 $  18,547
Operating income (loss) 3,566 (3,207) 6,773 12,949 2,548 10,401
Adjusted operating income(1) 4,194 3,459 735 14,501 11,846 2,655
Net income (loss) 2,171 (3,990) 6,161 8,123 (1,195) 9,318
Diluted earnings (loss) per share $     1.68 $    (3.13) $     4.81 $     6.29 $    (0.93) $     7.22
Adjusted EPS(2) $     2.09 $     1.60 $     0.49 $     7.24 $     5.66 $     1.58

For the three months ended September 30, 2026 compared to the prior year:

  • Total revenues increased 5.4% primarily driven by growth in the Health Services and Health Care Benefits segments.
  • During the three months ended September 30, 2026, the Company generated operating income of $3.6 billion compared to an operating loss of $3.2 billion in the prior year. The difference was primarily driven by the absence of the $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit recorded in the prior year and the increase in adjusted operating income described below.
  • Adjusted operating income increased 21.2% primarily driven by increases across all operating segments. See pages 3 through 5 for additional discussion of the adjusted operating income performance of the Company's segments.

Operational Updates

  • More than 69 percent of Aetna® Medicare Advantage members are in 2027 plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services. These results position Aetna second among large, publicly traded Medicare Advantage organizations in the Star Ratings program. For the third consecutive year, Aetna's commitment to care has driven strong performance across various clinical quality, preventive care and member experience measures.
  • CVS Health continues to lead the industry through enhancements to its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications. CVS Pharmacy offers all FDA-approved GLP-1s. Through its integrated offerings, CVS Health can combine a MinuteClinic digital weight loss visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and in-person pharmacist support in one connected experience, with no membership or recurring monthly fee.
  • Health100™, a CVS Health subsidiary, earned the CARIN Code of Conduct for Consumer-Facing Applications Accreditation from DirectTrust® for the Health100 mobile app. Health100 provides consumers with cost transparency and the ability to reduce out-of-pocket costs, helps them find and access expanded care, and offers integrated, simpler health care navigation and chronic condition management, including real-time proactive support to stay on track.

Health Care Benefits segment

The Health Care Benefits segment offers a full range of insured and self-insured ("ASC") medical, pharmacy, dental and behavioral health products and services. The segment results for the three and nine months ended September 30, 2026 and 2025 were as follows:

Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
In millions, except percentages 2026 2025 Change 2026 2025 Change
Total revenues $ 36,855 $ 35,993 $     862 $        110,364 $        107,061 $   3,303
Adjusted operating income(1) 912 314 598 6,379 3,615 2,764
Medical benefit ratio ("MBR")(3) 91.3 % 92.8 % (1.5) % 87.8 % 90.0 % (2.2) %
Medical membership(4) 26.1 26.7 (0.6)
  • Total revenues increased 2.4% for the three months ended September 30, 2026 compared to the prior year primarily driven by an increase in the Government business, partially offset by a decline as a result of the Company's exit of the individual exchange business in 2026.
  • Adjusted operating income increased significantly in the three months ended September 30, 2026 compared to the prior year primarily driven by improved underlying performance in the Government business.
  • The MBR decreased to 91.3% in the three months ended September 30, 2026 compared to 92.8% in the prior year primarily driven by improved underlying performance in the Government business.
  • Medical membership as of September 30, 2026 of 26.1 million remained consistent compared with June 30, 2026.
  • Prior years' health care costs payable estimates developed favorably by $1.3 billion during the nine months ended September 30, 2026.
  • Days claims payable were 41.9 days as of September 30, 2026, an increase of 0.2 days compared to June 30, 2026.

Health Services segment

The Health Services segment provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The segment results for the three and nine months ended September 30, 2026 and 2025 were as follows:

Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
In millions 2026 2025 Change 2026 2025 Change
Total revenues $  53,964 $  49,266 $   4,698 $ 153,996 $ 139,181 $  14,815
Adjusted operating income(1) 2,106 2,050 56 5,328 5,228 100
Pharmacy claims processed(5) (6) 481.7 475.6 6.1 1,419.4 1,408.8 10.6
  • Total revenues increased 9.5% for the three months ended September 30, 2026 compared to the prior year primarily driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements.

  • Adjusted operating income increased 2.7% for the three months ended September 30, 2026 compared to the prior year primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements.

  • Pharmacy claims processed increased 1.3% on a 30-day equivalent basis for the three months ended September 30, 2026 compared to the prior year.

Pharmacy & Consumer Wellness segment

The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise. The segment also provides pharmacy fulfillment services to support the Health Services segment's specialty and mail order pharmacy offerings. The segment results for the three and nine months ended September 30, 2026 and 2025 were as follows:

Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
In millions 2026 2025 Change 2026 2025 Change
Total revenues $  35,498 $  36,214 $    (716) $ 101,303 $ 101,707 $    (404)
Adjusted operating income(1) 1,635 1,478 157 4,307 4,129 178
Prescriptions filled(5) (6) 470.0 461.4 8.6 1,378.2 1,335.0 43.2
  • Total revenues decreased 2.0% for the three months ended September 30, 2026 compared to the prior year primarily driven by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure. These decreases were partially offset by pharmacy drug mix, increased prescription volume, including contributions from the Company's Rite Aid asset acquisitions which were completed during the third quarter of 2025, and brand inflation.
  • Adjusted operating income increased 10.6% for the three months ended September 30, 2026 compared to the prior year primarily driven by core pharmacy strength and contributions from the Company's Rite Aid asset acquisitions. These increases were partially offset by continued business investments and the impact of consumer dynamics.
  • Prescriptions filled increased 1.9% on a 30-day equivalent basis for the three months ended September 30, 2026 compared to the prior year primarily driven by increased utilization and incremental volume resulting from the Company's Rite Aid prescription file acquisitions, partially offset by the absence of long-term care pharmacy prescription volume following the deconsolidation of Omnicare, LLC ("Omnicare") in September 2025.

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of September 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Teleconference and Webcast

The Company will be holding a conference call today for investors at 8:00 a.m. (Eastern Time) to discuss its third quarter results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com . This webcast will be archived and available on the website for a one-year period following the conference call.

Non-GAAP Financial Information

The Company presents both GAAP and non-GAAP financial measures in this press release to assist in the comparison of the Company's past financial performance with its current financial performance. See "Non-GAAP Financial Information" beginning on page 10 and endnotes beginning on page 20 for explanations of non-GAAP financial measures presented in this press release. See pages 12 through 14 and page 19 for reconciliations of each non-GAAP financial measure used in this release to the most directly comparable GAAP financial measure.

Cautionary Statement Concerning Forward-looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, the full-year 2026 guidance information, Mr. Joyner's quotation and the information included in the reconciliations and endnotes. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission ("SEC") filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2026, June 30, 2026 and September 30, 2026 and our Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health's forward-looking statements. CVS Health's forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

- Tables Follow -

CVS HEALTH CORPORATIONCondensed Consolidated Statements of Operations(Unaudited)
Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
In millions, except per share amounts 2026 2025 2026 2025
Revenues:
Products $     69,225 $     64,590 $   197,670 $   182,866
Premiums 34,566 33,719 103,474 100,734
Services 3,961 3,930 11,915 11,135
Net investment income 647 632 1,862 1,639
Total revenues 108,399 102,871 314,921 296,374
Operating costs:
Cost of products sold 61,185 57,045 175,491 162,107
Health care costs 32,316 32,020 93,159 92,472
Operating expenses 11,332 11,288 33,322 33,522
Goodwill impairment — 5,725 — 5,725
Total operating costs 104,833 106,078 301,972 293,826
Operating income (loss) 3,566 (3,207) 12,949 2,548
Gain on deconsolidation of subsidiary — 483 — 483
Interest expense (747) (784) (2,278) (2,332)
Other income 30 26 93 83
Income (loss) before income tax provision 2,849 (3,482) 10,764 782
Income tax provision 678 508 2,641 1,977
Net income (loss) 2,171 (3,990) 8,123 (1,195)
Net (income) loss attributable to noncontrolling interests 1 15 (29) 20
Net income (loss) attributable to CVS Health $      2,172 $     (3,975) $      8,094 $     (1,175)
Net income (loss) per share attributable to CVS Health:
Basic $        1.70 $      (3.13) $        6.33 $      (0.93)
Diluted $        1.68 $      (3.13) $        6.29 $      (0.93)
Weighted average shares outstanding:
Basic 1,282 1,269 1,278 1,266
Diluted 1,291 1,269 1,286 1,266
CVS HEALTH CORPORATIONCondensed Consolidated Balance Sheets(Unaudited)
In millions September 30, 2026 December 31, 2025
Assets:
Cash and cash equivalents $         11,738 $           8,453
Investments 3,149 2,145
Accounts receivable, net 42,073 39,779
Inventories 18,240 19,246
Other current assets 4,192 5,091
Total current assets 79,392 74,714
Long-term investments 34,066 32,669
Property and equipment, net 13,322 13,083
Operating lease right-of-use assets 14,226 14,973
Goodwill 85,478 85,478
Intangible assets, net 24,224 25,508
Other assets 7,367 7,113
Total assets $       258,075 $       253,538
Liabilities:
Accounts payable $         17,875 $         17,641
Pharmacy claims and discounts payable 26,296 26,344
Health care costs payable 16,858 15,399
Accrued expenses and other current liabilities 25,787 22,387
Other insurance liabilities 904 1,116
Current portion of operating lease liabilities 1,920 1,737
Current portion of long-term debt 3,457 4,068
Total current liabilities 93,097 88,692
Long-term operating lease liabilities 12,697 13,643
Long-term debt 57,223 60,502
Deferred income taxes 3,866 3,832
Other long-term insurance liabilities 4,231 4,716
Other long-term liabilities 6,272 6,771
Total liabilities 177,386 178,156
Shareholders' equity:
Preferred stock — —
Common stock and capital surplus 51,154 50,402
Treasury stock (36,769) (36,790)
Retained earnings 66,707 61,196
Accumulated other comprehensive income (loss) (595) 406
Total CVS Health shareholders' equity 80,497 75,214
Noncontrolling interests 192 168
Total shareholders' equity 80,689 75,382
Total liabilities and shareholders' equity $       258,075 $       253,538
CVS HEALTH CORPORATIONCondensed Consolidated Statements of Cash Flows(Unaudited)
Nine Months EndedSeptember 30,
In millions 2026 2025
Cash flows from operating activities:
Reconciliation of net income (loss) to net cash provided by operating activities:
Net income (loss) $        8,123 $      (1,195)
Adjustments required to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization 3,373 3,459
Goodwill impairment — 5,725
Stock-based compensation 610 400
Loss on sale of subsidiary — 236
Gain on deconsolidation of subsidiary — (483)
Deferred income taxes and other items (344) (440)
Change in operating assets and liabilities 3,556 (453)
Net cash provided by operating activities 15,318 7,249
Cash flows from investing activities:
Proceeds from sales and maturities of investments 10,382 9,640
Purchases of investments (13,592) (11,045)
Purchases of property and equipment (2,357) (2,048)
Acquisitions (15) (429)
Other 37 9
Net cash used in investing activities (5,545) (3,873)
Cash flows from financing activities:
Commercial paper borrowings (repayments), net — (872)
Proceeds from issuance of long-term debt — 3,969
Repayments of long-term debt (4,057) (3,609)
Dividends paid (2,578) (2,552)
Proceeds from exercise of stock options 339 308
Payments for taxes related to net share settlement of equity awards (175) (145)
Other (66) (7)
Net cash used in financing activities (6,537) (2,908)
Net increase in cash, cash equivalents and restricted cash 3,236 468
Cash, cash equivalents and restricted cash at the beginning of the period 8,712 8,884
Cash, cash equivalents and restricted cash at the end of the period $      11,948 $        9,352

Non-GAAP Financial Information

The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company's and investors' ability to compare the Company's past financial performance with its current and expected future performance. These non-GAAP financial measures, which are included in this press release and which may be referred to on the conference call discussing the Company's third quarter financial results, are provided as supplemental information to the financial measures presented in this press release and discussed on the conference call that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company's definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies.

Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share ("EPS") and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance.

For the periods covered in this press release, the following items are excluded from the non-GAAP financial measures described above, as applicable, because the Company believes they neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance:

  • The Company's acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in operating expenses within each segment. Although intangible assets contribute to the Company's revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company's insurance products, the services performed for the Company's customers or the sale of the Company's products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company's acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company's GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
  • The Company's net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. Net realized capital gains and losses are reflected in net investment income (loss) within each segment. These capital gains and losses are the result of investment decisions, market conditions and other economic developments that are unrelated to the performance of the Company's business, and the amount and timing of these capital gains and losses do not directly relate to the underwriting of the Company's insurance products, the services performed for the Company's customers or the sale of the Company's products or services. Accordingly, the Company believes excluding net realized capital gains and losses enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance and to analyze underlying business performance and trends.
  • During the three and nine months ended September 30, 2026 and 2025, the acquisition-related integration costs relate to the acquisitions of Signify Health, Inc. and Oak Street Health, Inc. The acquisition-related integration costs are reflected in operating expenses within the Corporate/Other segment.
  • During the three and nine months ended September 30, 2026, the Omnicare guarantee relates to an estimated contingent guarantee liability recorded in connection with agreements to resolve certain litigation and Chapter 11 bankruptcy matters involving Omnicare. Following bankruptcy court approval of the agreements in August 2026 and the determination that the sale of Omnicare's assets is probable of occurring in the fourth quarter of 2026, the Company recorded an estimated contingent guarantee liability in the third quarter of 2026. The Omnicare guarantee is reflected in operating expenses within the Corporate/Other Segment.
  • During the three and nine months ended September 30, 2025, the goodwill impairment charge relates to the Health Care Delivery reporting unit within the Health Services segment.
  • During the three and nine months ended September 30, 2025, the Health Care Delivery clinic closure charge primarily relates to the write down of long-lived assets in connection with the closure of certain Oak Street Health clinics in 2026, as well as associated severance and employee-related costs. The Health Care Delivery clinic closure charge was reflected in operating expenses within the Health Services segment.
  • During the three and nine months ended September 30, 2025, the opioid litigation charge relates to a change in the Company's accrual related to ongoing opioid litigation matters.
  • During the nine months ended September 30, 2025, the Company recorded legacy litigation charges related to two court decisions associated with its past business practices. The legacy litigation charges were reflected in operating expenses within the Pharmacy & Consumer Wellness and Health Services segments.
  • During the nine months ended September 30, 2025, the loss on the wind down and sale of Accountable Care assets represents the pre-tax loss on the divestiture of the Company's Medicare Shared Savings Program ("MSSP") operations, as well as costs incurred in connection with the wind down of the Company's ACO REACH operations. The loss on Accountable Care assets was reflected in operating expenses within the Health Services segment.
  • During the nine months ended September 30, 2025, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company's evaluation of corporate office real estate space. The office real estate optimization charges were reflected in operating expenses within each segment.
  • During the three and nine months ended September 30, 2025, the gain on deconsolidation of subsidiary relates to Omnicare, a wholly-owned indirect subsidiary of CVS Health Corporation, and certain of its subsidiary entities (collectively, the "Omnicare Entities"). In September 2025, the Omnicare Entities voluntarily initiated Chapter 11 proceedings under the U.S. Bankruptcy Code, at which time the Company determined that it no longer retained control of the Omnicare Entities and deconsolidated the subsidiaries.
  • The corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.

See endnotes (1) and (2) on page 20 for definitions of non-GAAP financial measures. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented on pages 12 through 14 and page 19.

Reconciliations of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures Adjusted Operating Income(Unaudited)
The following are reconciliations of consolidated operating income (loss) (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income (loss) to segment adjusted operating income (loss):
Three Months Ended September 30, 2026
In millions Health CareBenefits HealthServices Pharmacy &ConsumerWellness Corporate/Other ConsolidatedTotals
Operating income (loss) (GAAP measure) $        653 $    1,980 $        1,573 $      (640) $        3,566
Amortization of intangible assets 236 126 62 1 425
Net realized capital (gains) losses 23 — — (26) (3)
Acquisition-related integration costs — — — 13 13
Omnicare guarantee — — — 193 193
Adjusted operating income (loss)(1) $        912 $    2,106 $        1,635 $      (459) $        4,194
Three Months Ended September 30, 2025
In millions Health CareBenefits HealthServices Pharmacy &ConsumerWellness Corporate/Other ConsolidatedTotals
Operating income (loss) (GAAP measure) $          53 $   (3,899) $        1,414 $      (775) $      (3,207)
Amortization of intangible assets 294 141 64 1 500
Net realized capital (gains) losses (33) — — 44 11
Acquisition-related integration costs — — — 27 27
Goodwill impairment — 5,725 — — 5,725
Health Care Delivery clinic closure charge — 83 — — 83
Opioid litigation charge — — — 320 320
Adjusted operating income (loss)(1) $        314 $    2,050 $        1,478 $      (383) $        3,459
Nine Months Ended September 30, 2026
In millions Health CareBenefits HealthServices Pharmacy &ConsumerWellness Corporate/Other ConsolidatedTotals
Operating income (loss) (GAAP measure) $      5,650 $    4,930 $        4,118 $    (1,749) $      12,949
Amortization of intangible assets 709 398 189 2 1,298
Net realized capital losses 20 — — 6 26
Acquisition-related integration costs — — — 35 35
Omnicare guarantee — — — 193 193
Adjusted operating income (loss)(1) $      6,379 $    5,328 $        4,307 $    (1,513) $      14,501
Nine Months Ended September 30, 2025
In millions Health CareBenefits HealthServices Pharmacy &ConsumerWellness Corporate/Other ConsolidatedTotals
Operating income (loss) (GAAP measure) $      2,729 $   (1,570) $        3,014 $    (1,625) $        2,548
Amortization of intangible assets 881 426 184 2 1,493
Net realized capital (gains) losses 1 (15) — 73 59
Acquisition-related integration costs — — — 100 100
Goodwill impairment — 5,725 — — 5,725
Health Care Delivery clinic closure charge — 83 — — 83
Opioid litigation charge — — — 320 320
Legacy litigation charges — 291 929 — 1,220
Loss on Accountable Care assets — 288 — — 288
Office real estate optimization charges 4 — 2 4 10
Adjusted operating income (loss)(1) $      3,615 $    5,228 $        4,129 $    (1,126) $      11,846
Adjusted Earnings Per Share(Unaudited)
The following are reconciliations of net income (loss) attributable to CVS Health to adjusted income attributable to CVS Health and calculations of GAAP diluted earnings (loss) per share and Adjusted EPS:
Three Months EndedSeptember 30, 2026 Three Months EndedSeptember 30, 2025
In millions, except per share amounts Total Company Per Common Share Total Company Per Common Share
Net income (loss) attributable to CVS Health (GAAP measure) $     2,172 $      1.68 $   (3,975) $     (3.13)
Amortization of intangible assets 425 0.33 500 0.39
Net realized capital (gains) losses (3) — 11 0.01
Acquisition-related integration costs 13 0.01 27 0.02
Omnicare guarantee 193 0.15 — —
Goodwill impairment — — 5,725 4.50
Health Care Delivery clinic closure charge — — 83 0.07
Opioid litigation charge — — 320 0.25
Gain on deconsolidation of subsidiary — — (483) (0.38)
Tax impact of non-GAAP adjustments (103) (0.08) (171) (0.13)
Adjusted income attributable to CVS Health(2) $     2,697 $      2.09 $     2,037 $      1.60
Weighted average diluted shares outstanding 1,291 1,269
Adjusted weighted average diluted shares outstanding (non- GAAP)(2) 1,291 1,272
Nine Months EndedSeptember 30, 2026 Nine Months EndedSeptember 30, 2025
In millions, except per share amounts Total Company Per Common Share Total Company Per Common Share
Net income (loss) attributable to CVS Health (GAAP measure) $     8,094 $      6.29 $   (1,175) $     (0.93)
Amortization of intangible assets 1,298 1.01 1,493 1.18
Net realized capital losses 26 0.02 59 0.05
Acquisition-related integration costs 35 0.03 100 0.08
Omnicare guarantee 193 0.15 — —
Goodwill impairment — — 5,725 4.50
Health Care Delivery clinic closure charge — — 83 0.07
Opioid litigation charge — — 320 0.25
Legacy litigation charges — — 1,220 0.96
Loss on Accountable Care assets — — 288 0.23
Office real estate optimization charges — — 10 0.01
Gain on deconsolidation of subsidiary — — (483) (0.38)
Tax impact of non-GAAP adjustments (333) (0.26) (455) (0.36)
Adjusted income attributable to CVS Health(2) $     9,313 $      7.24 $     7,185 $      5.66
Weighted average diluted shares outstanding 1,286 1,266
Adjusted weighted average diluted shares outstanding (non- GAAP)(2) 1,286 1,269
Supplemental Information(Unaudited)
The following are reconciliations of financial measures of the Company's segments to the consolidated totals:
In millions Health CareBenefits HealthServices Pharmacy &ConsumerWellness Corporate/Other IntersegmentEliminations (a) ConsolidatedTotals
Three Months Ended
September 30, 2026
Total revenues $    36,855 $  53,964 $        35,498 $       205 $      (18,123) $    108,399
Adjusted operating income (loss)(1) 912 2,106 1,635 (459) — 4,194
September 30, 2025
Total revenues $    35,993 $  49,266 $        36,214 $       133 $      (18,735) $    102,871
Adjusted operating income (loss)(1) 314 2,050 1,478 (383) — 3,459
Nine Months Ended
September 30, 2026
Total revenues $  110,364 $ 153,996 $      101,303 $       478 $      (51,220) $    314,921
Adjusted operating income (loss)(1) 6,379 5,328 4,307 (1,513) — 14,501
September 30, 2025
Total revenues $  107,061 $ 139,181 $      101,707 $       362 $      (51,937) $    296,374
Adjusted operating income (loss)(1) 3,615 5,228 4,129 (1,126) — 11,846
(a) Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment.
Supplemental Information(Unaudited)
Health Care Benefits segment The following table summarizes the Health Care Benefits segment's performance for the respective periods:
Change
Three Months EndedSeptember 30, Nine Months EndedSeptember 30, Three Months EndedSeptember 30,2026 vs 2025 Nine Months EndedSeptember 30,2026 vs 2025
In millions, except percentages and basis points ("bps") 2026 2025 2026 2025 $ % $ %
Revenues:
Premiums $  34,569 $  33,739 $ 103,480 $ 100,731 $     830 2.5 % $  2,749 2.7 %
Services 1,831 1,741 5,459 5,023 90 5.2 % 436 8.7 %
Net investment income 455 513 1,425 1,307 (58) (11.3) % 118 9.0 %
Total revenues 36,855 35,993 110,364 107,061 862 2.4 % 3,303 3.1 %
Health care costs 31,556 31,319 90,827 90,696 237 0.8 % 131 0.1 %
MBR (Health care costs as a % of premium revenues)(3) 91.3 % 92.8 % 87.8 % 90.0 % (150) bps (220) bps
Operating expenses $ 4,646 $ 4,621 $ 13,887 $  13,636 $      25 0.5 % $     251 1.8 %
Operating expenses as a % of total revenues 12.6 % 12.8 % 12.6 % 12.7 %
Operating income $   653 $     53 $   5,650 $ 2,729 $     600 1,132.1 % $  2,921 107.0 %
Operating income as a % of total revenues 1.8 % 0.1 % 5.1 % 2.5 %
Adjusted operating income(1) $   912 $   314 $   6,379 $ 3,615 $     598 190.4 % $  2,764 76.5 %
Adjusted operating income as a % of total revenues 2.5 % 0.9 % 5.8 % 3.4 %
Premium revenues (by business):
Government $  28,108 $  25,968 $ 84,385 $  76,800 $  2,140 8.2 % $  7,585 9.9 %
Commercial 6,461 7,771 19,095 23,931 (1,310) (16.9) % (4,836) (20.2) %
The following table summarizes the Health Care Benefits segment's medical membership for the respective periods:
September 30, 2026 June 30, 2026 December 31, 2025 September 30, 2025
In thousands Insured ASC Total Insured ASC Total Insured ASC Total Insured ASC Total
Medical membership:(4)
Commercial 2,565 15,839 18,404 2,487 15,833 18,320 3,447 15,350 18,797 3,536 15,314 18,850
Medicare Advantage 4,229 — 4,229 4,202 — 4,202 4,267 — 4,267 4,266 — 4,266
Medicare Supplement 1,164 — 1,164 1,176 — 1,176 1,202 — 1,202 1,221 — 1,221
Medicaid 1,961 362 2,323 1,964 361 2,325 1,952 373 2,325 1,978 388 2,366
Total medical membership 9,919 16,201 26,120 9,829 16,194 26,023 10,868 15,723 26,591 11,001 15,702 26,703
Supplemental membership information:
Medicare Prescription Drug Plan (stand-alone) 3,858 3,870 4,041 4,056
The following table summarizes the Health Care Benefits segment's days claims payable for the respective periods:
September 30, 2026 June 30, 2026 December 31, 2025 September 30, 2025
Days Claims Payable(7) 41.9 41.7 38.9 42.5
Supplemental Information(Unaudited)
Health Services segment The following table summarizes the Health Services segment's performance for the respective periods:
Change
Three Months EndedSeptember 30, Nine Months EndedSeptember 30, Three Months EndedSeptember 30,2026 vs 2025 Nine Months EndedSeptember 30,2026 vs 2025
In millions, except percentages 2026 2025 2026 2025 $ % $ %
Revenues:
Products $ 51,491 $ 46,767 $  146,433 $  132,125 $  4,724 10.1 % $  14,308 10.8 %
Services 2,473 2,500 7,564 7,046 (27) (1.1) % 518 7.4 %
Net investment income (loss) — (1) (1) 10 1 100.0 % (11) (110.0) %
Total revenues 53,964 49,266 153,996 139,181 4,698 9.5 % 14,815 10.6 %
Cost of products sold 49,711 45,230 142,338 128,425 4,481 9.9 % 13,913 10.8 %
Health care costs 1,346 1,291 3,998 3,439 55 4.3 % 559 16.3 %
Gross profit(8) 2,907 2,745 7,660 7,317 162 5.9 % 343 4.7 %
Gross margin (Gross profit as a % of total revenues)(8) 5.4 % 5.6 % 5.0 % 5.3 %
Operating expenses $    927 $    919 $  2,730 $  3,162 $       8 0.9 % $    (432) (13.7) %
Operating expenses as a % of total revenues 1.7 % 1.9 % 1.8 % 2.3 %
Goodwill impairment $     — $  5,725 $     — $  5,725 $ (5,725) (100.0) % $ (5,725) (100.0) %
Operating income (loss) 1,980 (3,899) 4,930 (1,570) 5,879 150.8 % 6,500 414.0 %
Operating income (loss) as a % of total revenues 3.7 % (7.9) % 3.2 % (1.1) %
Adjusted operating income(1) $  2,106 $  2,050 $  5,328 $  5,228 $      56 2.7 % $     100 1.9 %
Adjusted operating income as a % of total revenues 3.9 % 4.2 % 3.5 % 3.8 %
Pharmacy claims processed(5) (6) 481.7 475.6 1,419.4 1,408.8 6.1 1.3 % 10.6 0.8 %
Supplemental Information(Unaudited)
Pharmacy & Consumer Wellness segment The following table summarizes the Pharmacy & Consumer Wellness segment's performance for the respective periods:
Change
Three Months EndedSeptember 30, Nine Months EndedSeptember 30, Three Months EndedSeptember 30,2026 vs 2025 Nine Months EndedSeptember 30,2026 vs 2025
In millions, except percentages 2026 2025 2026 2025 $ % $ %
Revenues:
Products $ 34,807 $ 35,503 $ 99,298 $ 99,730 $   (696) (2.0) % $   (432) (0.4) %
Services 691 711 2,005 1,977 (20) (2.8) % 28 1.4 %
Total revenues 35,498 36,214 101,303 101,707 (716) (2.0) % (404) (0.4) %
Cost of products sold 28,700 29,647 81,772 83,005 (947) (3.2) % (1,233) (1.5) %
Gross profit(8) 6,798 6,567 19,531 18,702 231 3.5 % 829 4.4 %
Gross margin (Gross profit as a % of total revenues)(8) 19.2 % 18.1 % 19.3 % 18.4 %
Operating expenses $ 5,225 $  5,153 $ 15,413 $ 15,688 $      72 1.4 % $   (275) (1.8) %
Operating expenses as a % of total revenues 14.7 % 14.2 % 15.2 % 15.4 %
Operating income $ 1,573 $  1,414 $  4,118 $  3,014 $     159 11.2 % $  1,104 36.6 %
Operating income as a % of total revenues 4.4 % 3.9 % 4.1 % 3.0 %
Adjusted operating income(1) $ 1,635 $  1,478 $  4,307 $  4,129 $     157 10.6 % $     178 4.3 %
Adjusted operating income as a % of total revenues 4.6 % 4.1 % 4.3 % 4.1 %
Revenues (by major goods/service lines):
Pharmacy $ 29,725 $ 30,428 $ 83,629 $ 84,135 $   (703) (2.3) % $   (506) (0.6) %
Front Store 5,164 5,192 15,830 15,803 (28) (0.5) % 27 0.2 %
Other 609 594 1,844 1,769 15 2.5 % 75 4.2 %
Prescriptions filled(5) (6) 470.0 461.4 1,378.2 1,335.0 8.6 1.9 % 43.2 3.2 %
Same store sales increase (decrease):(9)
Total (0.6) % 14.3 % 1.5 % 14.6 %
Pharmacy (0.6) % 16.8 % 1.7 % 17.5 %
Front Store (0.6) % 1.5 % 0.5 % 1.5 %
Prescription volume(6) 3.9 % 8.9 % 5.8 % 7.3 %
Adjusted Earnings Per Share Guidance(Unaudited)
The following reconciliations of projected net income attributable to CVS Health to projected adjusted income attributable to CVS Health and calculations of projected GAAP diluted EPS and projected Adjusted EPS contain forward-looking information. All forward-looking information involves risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking information for a number of reasons as described in our SEC filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K and our most recently filed Quarterly Report on Form 10-Q. See "Non-GAAP Financial Information" earlier in this press release and endnote (2) later in this press release for more information on how we calculate Adjusted EPS.
Year EndingDecember 31, 2026
At Least
In millions, except per share amounts Total Company Per Common Share
Net income attributable to CVS Health (GAAP measure) $     9,002 $       6.98
Non-GAAP adjustments:
Amortization of intangible assets 1,730 1.34
Net realized capital losses 26 0.02
Acquisition-related integration costs 80 0.06
Omnicare guarantee 193 0.15
Tax impact of non-GAAP adjustments (460) (0.35)
Adjusted income attributable to CVS Health(2) $   10,571 $       8.20
Weighted average diluted shares outstanding 1,289

Endnotes

(1)  The Company defines adjusted operating income as operating income (loss) (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related integration costs, the Omnicare guarantee, goodwill impairment charges, Health Care Delivery clinic closure charges, opioid litigation charges, certain legacy litigation charges, losses on Accountable Care assets and office real estate optimization charges. The chief operating decision maker (the "CODM") uses adjusted operating income as its principal measure of segment performance as it enhances the CODM's ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income (loss). See "Non-GAAP Financial Information" earlier in this press release for additional information regarding the items excluded from consolidated operating income (loss) in determining consolidated adjusted operating income.

(2)  GAAP diluted earnings (loss) per share and Adjusted EPS, respectively, are calculated by dividing net income (loss) attributable to CVS Health and adjusted income attributable to CVS Health by the Company's weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income (loss) attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related integration costs, the Omnicare guarantee, goodwill impairment charges, Health Care Delivery clinic closure charges, opioid litigation charges, certain legacy litigation charges, losses on Accountable Care assets, office real estate optimization charges, the gain on deconsolidation of subsidiary, as well as the corresponding income tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health. Adjusted EPS for the three and nine months ended September 30, 2025 is calculated utilizing weighted average diluted shares outstanding, which include potential common shares in each period, as the impact of the potential common shares was dilutive. The potential common shares were excluded from the calculations of GAAP loss per share for the three and nine months ended September 30, 2025, as the shares would have had an anti-dilutive effect as a result of the GAAP net loss in each period. See "Non-GAAP Financial Information" earlier in this press release for additional information regarding the items excluded from net income (loss) attributable to CVS Health in determining adjusted income attributable to CVS Health.

(3)  Medical benefit ratio is calculated by dividing the Health Care Benefits segment's health care costs by premium revenues and represents the percentage of premium revenues spent on medical benefits for the segment's insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Health Care Benefits segment's insured products.

(4)  Medical membership represents the number of members covered by the Health Care Benefits segment's insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on the Health Care Benefits segment's total revenues and operating results.

(5)  Pharmacy claims processed represents the number of prescription claims processed through the Company's pharmacy benefits manager and dispensed by either its retail network pharmacies or the Company's mail and specialty pharmacies. Prescriptions filled represents the number of prescriptions dispensed through the Pharmacy & Consumer Wellness segment's retail pharmacies and infusion services operations, as well as through the Omnicare long-term care pharmacies prior to their deconsolidation in September 2025. Management uses these metrics to understand variances between actual claims processed and prescriptions dispensed, respectively, and expected amounts as well as trends in period-over-period results. These metrics provide management and investors with information useful in understanding the impact of pharmacy claim volume and prescription volume, respectively, on segment total revenues and operating results.

(6)  Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription. 

(7)  Days claims payable is calculated by dividing the Health Care Benefits segment's health care costs payable at the end of each quarter by its average health care costs per day during such quarter. Management and investors use this metric as one of the indicators of the adequacy of the health care costs payable liability at the end of each quarter.

(8)  Gross profit is calculated as the segment's total revenues less its cost of products sold, and, for the Health Services segment, health care costs. Gross margin is calculated by dividing the segment's gross profit by its total revenues and represents the percentage of total revenues that remains after incurring direct costs associated with the segment's products sold and services provided. Gross margin provides investors with information that may be useful in assessing the operating results of the Company's Health Services and Pharmacy & Consumer Wellness segments.

(9)  Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company's retail pharmacy stores that have been operating for greater than one year and digital sales initiated online or through mobile applications and fulfilled through the Company's distribution centers, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues and prescriptions from infusion services operations and long-term care pharmacies. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.

CVS Health logo (PRNewsFoto/CVS Health)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance-302928358.html

SOURCE CVS Health

View All News

November 4, 2026

  • A leading healthcare solutions company with health benefits, pharmacy services and care delivery

  • The leading national retail pharmacy and community healthcare company

  • Ongoing strategic execution creates opportunity for CVS Health to evolve into two companies with greater focus and more value for stakeholders

  • Will continue to improve affordability, access, and simplicity in healthcare

  • Both companies expected to have a solid investment grade rating, with strong free cash flow generation, flexibility for strategic capital deployment and an attractive dividend

  • _Expected to be completed in the first half of 2028 by means of a separation that is intended to be tax-free to CVS Health and its shareholders

    _

  • CVS Health to host investor conference call today at 8 a.m. ET

WOONSOCKET, R.I., Nov. 4, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that it intends to separate into two independent, publicly traded companies, each committed to innovating to make healthcare more affordable, accessible, and simpler to navigate for the millions of people each serves. The decision follows a comprehensive strategic review by the CVS Health Board of Directors.

CVS Health (PRNewsFoto/CVS Health)

The planned separation will create two companies:

  • A leading healthcare solutions company, comprising Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The healthcare solutions company, in the interim, will be referred to as CVS Health.
  • The leading national retail pharmacy and community healthcare company, comprising approximately 9,000 CVS pharmacies, mail pharmacy, MinuteClinic (including virtual care), and the Health100 technology services business. This company will be named CVS Pharmacy.

Upon separation, David Joyner, currently Chairman and CEO of CVS Health, will be the Chairman and CEO of the healthcare solutions company, and Prem Shah, currently Group President of CVS Health, will be the CEO of CVS Pharmacy. Additional leadership positions and Board members will be announced at a later date.

"Our history is defined by proactively evolving to stay ahead of what's next in healthcare, and in today's environment, that means delivering more affordability, greater access, and a simpler experience," said Joyner. "Over the last two years, we have made meaningful progress: we built a world-class leadership team, strengthened our financials, revitalized operations across the enterprise, and drove total shareholder return. From a position of strength, and a focus on the long term, we plan to create two focused companies to improve consumer engagement, affordability, and care coordination."

Joyner continued, "Aetna, CVS Caremark and CVS Specialty, along with our value-based care and in-home health businesses, will advance together as a leading healthcare solutions provider, delivering differentiated, comprehensive benefits to clients, members and patients. CVS Pharmacy will build on its position as America's leading retail pharmacy, serving as the front door to health and care in our country as the most frequently accessed consumer health touchpoint. Both companies will continue to advance innovative technology solutions to improve the healthcare experience as we deliver on our purpose to simplify healthcare, one person, one family and one community at a time."

Accelerating Our Strategy

The planned separation accelerates our strategy, which consists of four priorities to create sustainable value: deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness enterprise capabilities.

As independent companies, each will benefit from:

  • A focused strategic agenda with an experienced and dedicated leadership team
  • An independent capital structure and strong free cash flow, which enables each company to pursue disciplined and tailored capital allocation to drive its own strategic priorities
  • Greater agility to innovate, adopt technology, increase efficiency and proactively adapt to regulatory and other external dynamics
  • A simplified structure to better serve consumers, members, communities, patients, and colleagues

The healthcare solutions company, CVS Health, will maintain the connections that drive value for clients and members, enabling it to lower costs while improving health outcomes and experiences. This combination of assets will enable it to continue to drive differentiated innovations to address the country's healthcare needs.

The pharmacy company, CVS Pharmacy, will continue to serve as the most frequent healthcare touchpoint for communities across the nation. As an independent company, CVS Pharmacy will continue to expand the services provided by its nearly 30,000 pharmacists and pursue a wider set of partnerships across the healthcare system, including with payers, pharmacy benefit managers and manufacturers, to better serve the needs of consumers and patients.

An ongoing focus on advancing technology to improve healthcare will be a hallmark of both companies, as exemplified by the launch of Health100. Both companies remain committed to realizing the tremendous potential of Health100, which will deliver AI-native products and services designed to address today's affordability, access and experience challenges in healthcare.

The execution of the separation will not impact the company's continued focus on innovating and improving the quality care experience that its customers and consumers have come to expect. Customers, patients and clients will continue to receive their medicine, care, benefits and services, uninterrupted.  

Transaction Details

Upon completion, CVS Health shareholders will own shares in both companies. The separation is intended to be structured as tax-free to CVS Health and its shareholders for U.S. federal income tax purposes.

Both companies are expected to have a solid investment grade rating at the time of separation, each with the balance sheet capacity and strong free cash flow to invest in a focused set of strategic priorities and pay an attractive dividend.

The separation is expected to be completed in the first half of 2028, subject to customary conditions, including, among others, final approval by the CVS Health Board of Directors, effectiveness of a Form 10 registration statement filed with the U.S. Securities and Exchange Commission and receipt of customary confirmation about the tax-free treatment of the separation to CVS Health and its shareholders.

Until the completion of the separation, CVS Health will continue to operate, compete and serve customers as it does today, and deliver against its financial targets.

CVS Health will provide additional information as the separation process progresses.

Advisors

Goldman Sachs & Co. LLC is serving as lead financial advisor and strategic advisor to the company. Consello is also serving as financial and strategic advisor to the company. Wachtell, Lipton, Rosen & Katz is serving as legal counsel to the company.

Third Quarter 2026 Results and Conference Call

In a separate press release issued today, CVS Health announced its third quarter 2026 results and raised its full-year 2026 guidance.

CVS Health will host a conference call today for investors at 8:00 a.m. ET to discuss its third quarter results and the planned separation. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com . This webcast will be archived and available on the website for a one-year period following the conference call.

**About CVS Health
**CVS Health  is a leading health solutions company simplifying health care one person, one family and one community at a time. As of September 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Cautionary Statement Concerning Forward-Looking **Statements
**The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation (the "Company" or "CVS Health"). Statements in this press release that are forward-looking include, but are not limited to, statements regarding the proposed separation, the expected timeline for completing the separation, the structure and tax treatment of the separation, the expected credit profile, capital structure and dividend policies of each company, the anticipated composition and financial profile of each company, each company's expected strategy and financial performance,  each company's potential for future growth and outperformance, the expected benefits for both companies to be derived from the separation, the full year 2026 guidance referenced in this release and the forecast full year 2026 revenue and adjusted operating income of each company. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. There can be no assurance that the separation will occur, or that it will occur on the terms or timeline described. Actual results may differ materially from those contemplated by the forward-looking statements due to a number of risks and uncertainties and other factors including, among other things: uncertainties as to the structure and timing of the separation, the possibility that closing conditions for the separation may not be satisfied or waived, the risk that any consents or approvals required in connection with the separation may not be received, the impact of the separation on each company if the separation is completed, the possibility that the separation may not qualify for the expected tax treatment, the possibility that anticipated benefits from the separation may not be realized within the expected time frame or at all, the risk that the separation may be more difficult, time-consuming or costly than expected and the risk that dis-synergy costs, costs of restructuring transactions and other costs incurred in connection with the separation will exceed our estimates. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the Securities and Exchange Commission, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health's forward-looking statements. CVS Health's forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

Media contact:
Ethan Slavin, Executive Director, CVS Health Communications
860-273-6095

Investor **contact:
**Larry McGrath, Executive Vice President, Capital Markets
800-201-0938

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-announces-intent-to-create-two-distinct-leaders-in-healthcare-302928585.html

SOURCE CVS Health

View All News

Prompts

CVS Health Corporation (ticker CVS), listed in United States.

Company History

Date Change Detail
Sep 5, 2014 Renamed CVS CAREMARK CORP → CVS HEALTH CORP
Apr 28, 2011 Acquired Acquired Universal American Corp. (CIK 709878). Its filings from before the deal are on its own company page, not shown here.
Mar 23, 2007 Renamed CVS CORP → CVS/CAREMARK CORP

ETFs Holding CVS Health Corporation

ETF Weight in ETF Shares Market value As of
DUSA 5.28% 642,932 $ 67.141M Jul 31, 2026
GEND 4.47% 2,080 $ 217.214K Jul 31, 2026
CVGD 4.14% 54,893 $ 5.732M Jul 31, 2026
FMTM 3.17% 76,503 $ 7.989M Jul 31, 2026
CSTK 2.94% 49,622 $ 5.182M Jul 31, 2026
CLCV 2.73% 4,467 $ 466.489K Jul 31, 2026
DWLD 2.70% 158,312 $ 16.533M Jul 31, 2026
GQGU 2.53% 137,212 $ 14.195M Jun 30, 2026
YLDE 2.28% 35,480 $ 3.67M Jun 30, 2026
BUSA 1.97% 56,748 $ 5.871M Jun 30, 2026
SEPI 1.86% 27,386 $ 2.833M Jun 30, 2026
DVND 1.82% 9,298 $ 961.878K Jun 30, 2026
GKAT 1.75% 27,083 $ 2.802M Jun 30, 2026
PINK 1.70% 66,252 $ 5.685M Nov 17, 2026
ITAN 1.40% 20,092 $ 1.724M Nov 17, 2026
CGV 1.30% 16,100 $ 1.681M Jul 31, 2026
TMED 1.22% 2,717 $ 281.074K Jun 30, 2026
CVAR 1.21% 4,966 $ 518.599K Jul 31, 2026
BLCV 0.98% 39,623 $ 3.51M Nov 16, 2026
ROPE 0.97% 2,801 $ 240K Nov 18, 2026
CGCV 0.93% 257,282 $ 22.793M Nov 16, 2026
ABCS 0.92% 1,219 $ 114.476K Aug 31, 2026
GMOV 0.84% 9,535 $ 895.432K Aug 31, 2026
WBIG 0.82% 2,174 $ 224.9K Jun 30, 2026
LSEQ 0.80% 1,468 $ 131.166K Nov 13, 2026
VFMF 0.79% 82,337 $ 7.732M Aug 31, 2026
TVAL 0.79% 102,035 $ 9.039M Nov 17, 2026
NANC 0.74% 22,621 $ 2.004M Nov 17, 2026
UPSD 0.74% 8,286 $ 865.307K Jul 31, 2026
FBCV 0.72% 12,142 $ 1.268M Jul 31, 2026
CLSE 0.63% 60,376 $ 5.67M Aug 31, 2026
VFVA 0.62% 63,475 $ 5.961M Aug 31, 2026
VFMO 0.62% 126,503 $ 11.88M Aug 31, 2026
CAPE 0.60% 13,867 $ 1.435M Jun 30, 2026
LSVD 0.58% 36,106 $ 3.771M Jul 31, 2026
FLDZ 0.57% 225 $ 23.276K Jun 30, 2026
FFLV 0.57% 900 $ 93.987K Jul 31, 2026
CGBL 0.55% 490,314 $ 43.437M Nov 16, 2026
CGUS 0.54% 736,455 $ 65.243M Nov 16, 2026
LGDX 0.50% 7,778 $ 689.053K Nov 17, 2026
PEPS 0.46% 1,294 $ 133.864K Jun 30, 2026
SEIV 0.45% 63,996 $ 6.62M Jun 30, 2026
VUS 0.45% 768 $ 80.202K Jul 31, 2026
GSPY 0.42% 32,688 $ 2.896M Nov 17, 2026
DFUV 0.41% 711,898 $ 63.921M Nov 12, 2026
DFLV 0.41% 346,969 $ 31.154M Nov 12, 2026
FLCV 0.39% 5,710 $ 536.226K Aug 31, 2026
JAVA 0.36% 310,535 $ 26.647M Nov 17, 2026
FTLS 0.34% 98,503 $ 0.00 Nov 16, 2026
BALI 0.34% 59,499 $ 5.271M Nov 16, 2026
IALT 0.33% 299,329 $ 26.518M Nov 16, 2026
NBCR 0.31% 28,233 $ 2.651M Aug 31, 2026
FLCC 0.31% 4,359 $ 409.354K Aug 31, 2026
INFO 0.30% 35,518 $ 3.174M Nov 13, 2026
MODL 0.28% 27,906 $ 2.887M Jun 30, 2026
GVLU 0.27% 7,964 $ 705.531K Nov 17, 2026
SFTY 0.27% 22,431 $ 2.106M Aug 31, 2026
STOX 0.27% 6,342 $ 595.577K Aug 31, 2026
FELV 0.26% 81,620 $ 8.444M Jun 30, 2026
XMAG 0.26% 6,336 $ 568.909K Nov 13, 2026
LDRX 0.25% 6,671 $ 626.474K Aug 31, 2026
LCTU 0.23% 29,243 $ 2.591M Nov 16, 2026
SFGV 0.23% 30,535 $ 2.62M Nov 18, 2026
TACU 0.21% 436 $ 38.625K Nov 17, 2026
ADME 0.20% 5,697 $ 594.938K Jul 31, 2026
ACIO 0.20% 44,949 $ 4.694M Jul 31, 2026
VOXP 0.19% 108 $ 11.278K Jul 31, 2026
BDVL short -0.19% -37,376 $ -3.311M Nov 16, 2026
NTSX 0.18% 24,035 $ 2.486M Jun 30, 2026
NTSD 0.18% 606 $ 62.691K Jun 30, 2026
DFSU 0.18% 46,628 $ 4.187M Nov 12, 2026
IQSZ 0.17% 2,905 $ 303.369K Jul 31, 2026
JEPI 0.17% 927,038 $ 79.549M Nov 17, 2026
AAUS 0.17% 10,097 $ 870K Nov 18, 2026
DFUS 0.17% 402,098 $ 36.104M Nov 12, 2026
HCMT 0.16% 8,880 $ 927.338K Jul 31, 2026
APUE 0.16% 43,074 $ 4.045M Aug 31, 2026
ACVF 0.16% 2,271 $ 237.161K Jul 31, 2026
GDE 0.15% 7,829 $ 735.221K Aug 31, 2026
DYNF 0.15% 709,206 $ 62.829M Nov 16, 2026
JUSA 0.14% 14,224 $ 1.221M Nov 17, 2026
DFAU 0.14% 201,611 $ 18.103M Nov 12, 2026
DFAC 0.12% 1,192,739 $ 107.096M Nov 12, 2026
DXUV 0.12% 84,105 $ 7.552M Nov 12, 2026
INRO 0.12% 8,122 $ 719.528K Nov 16, 2026
MSLC 0.11% 48,180 $ 4.525M Aug 31, 2026
DCOR 0.10% 499,679 $ 44.866M Nov 12, 2026
EBI 0.07% 5,266 $ 494.53K Aug 31, 2026
CSHP 0.06% 2,655 $ 235.206K Nov 16, 2026
FBCG 0.05% 35,048 $ 3.66M Jul 31, 2026
AVUS 0.05% 86,276 $ 7.643M Nov 16, 2026
AVSU 0.05% 2,811 $ 249.026K Nov 16, 2026
AVLC 0.05% 9,399 $ 832.657K Nov 16, 2026
VSLU 0.02% 1,132 $ 117.105K Jun 30, 2026
ENHU 0.02% 26 $ 2,303.34 Nov 16, 2026
DFVX 0.01% 517 $ 46.421K Nov 12, 2026
NPFE 0.00% 276 $ 28.823K Jul 31, 2026
GEW 0.00% 53 $ 4,977.23 Aug 31, 2026
CORO 0.00% 807 $ 71.46K Nov 16, 2026